205 related articles for article (PubMed ID: 9734659)
1. Targeting of saporin to Hodgkin's lymphoma cells by anti-CD30 and anti-CD25 bispecific antibodies.
Sforzini S; de Totero D; Gaggero A; Ippoliti R; Glennie MJ; Canevari S; Stein H; Ferrini S
Br J Haematol; 1998 Sep; 102(4):1061-8. PubMed ID: 9734659
[TBL] [Abstract][Full Text] [Related]
2. Differential sensitivity of CD30+ neoplastic cells to gelonin delivered by anti-CD30/anti-gelonin bispecific antibodies.
Sforzini S; Bolognesi A; Meazza R; Marciano S; Casalini P; Dürkop H; Tazzari PL; Stein H; Stirpe F; Ferrini S
Br J Haematol; 1995 Jul; 90(3):572-7. PubMed ID: 7646996
[TBL] [Abstract][Full Text] [Related]
3. Targeting of saporin to CD25-positive normal and neoplastic lymphocytes by an anti-saporin/anti-CD25 bispecific monoclonal antibody: in vitro evaluation.
Tazzari PL; Zhang S; Chen Q; Sforzini S; Bolognesi A; Stirpe F; Xie H; Moretta A; Ferrini S
Br J Cancer; 1993 Jun; 67(6):1248-53. PubMed ID: 8512810
[TBL] [Abstract][Full Text] [Related]
4. Targeting of type 1 ribosome-inactivating proteins to CD30+ or CD25+ hematologic neoplasias by bispecific antibodies.
Sforzini S; Bolognesi A; Meazza R; Marciano S; Tazzari PL; Stein H; Stirpe F; Ferrini S
J Hematother; 1995 Oct; 4(5):429-32. PubMed ID: 8581380
[TBL] [Abstract][Full Text] [Related]
5. Anti-CD30 (BER=H2) immunotoxins containing the type-1 ribosome-inactivating proteins momordin and PAP-S (pokeweed antiviral protein from seeds) display powerful antitumour activity against CD30+ tumour cells in vitro and in SCID mice.
Terenzi A; Bolognesi A; Pasqualucci L; Flenghi L; Pileri S; Stein H; Kadin M; Bigerna B; Polito L; Tazzari PL; Martelli MF; Stirpe F; Falini B
Br J Haematol; 1996 Mar; 92(4):872-9. PubMed ID: 8616080
[TBL] [Abstract][Full Text] [Related]
6. CD30-antigen-specific targeting and activation of T cells via murine bispecific monoclonal antibodies against CD3 and CD28: potential use for the treatment of Hodgkin's lymphoma.
Pohl C; Denfeld R; Renner C; Jung W; Bohlen H; Sahin U; Hombach A; van Lier R; Schwonzen M; Diehl V
Int J Cancer; 1993 Jul; 54(5):820-7. PubMed ID: 7686889
[TBL] [Abstract][Full Text] [Related]
7. Ber-H2 (anti-CD30)-saporin immunotoxin: a new tool for the treatment of Hodgkin's disease and CD30+ lymphoma: in vitro evaluation.
Tazzari PL; Bolognesi A; de Totero D; Falini B; Lemoli RM; Soria MR; Pileri S; Gobbi M; Stein H; Flenghi L
Br J Haematol; 1992 Jun; 81(2):203-11. PubMed ID: 1322690
[TBL] [Abstract][Full Text] [Related]
8. In vivo and in vitro uptake of an anti-CD30/saporin immunotoxin by rat liver parenchymal and nonparenchymal cells.
Battelli MG; Buonamici L; Bolognesi A; Stirpe F
Hepatology; 1994 Oct; 20(4 Pt 1):940-7. PubMed ID: 7927236
[TBL] [Abstract][Full Text] [Related]
9. Delivery of the ribosome-inactivating protein, gelonin, to lymphoma cells via CD22 and CD38 using bispecific antibodies.
French RR; Penney CA; Browning AC; Stirpe F; George AJ; Glennie MJ
Br J Cancer; 1995 May; 71(5):986-94. PubMed ID: 7734325
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the performance of anti-CD7 and anti-CD38 bispecific antibodies and immunotoxins for the delivery of saporin to a human T-cell acute lymphoblastic leukemia cell line.
Flavell DJ; Cooper S; Okayama K; Emery L; Flavell SU
Hematol Oncol; 1995; 13(4):185-200. PubMed ID: 7557895
[TBL] [Abstract][Full Text] [Related]
11. Immunotoxins containing saporin linked to different CD2 monoclonal antibodies: in vitro evaluation.
Tazzari PL; Bolognesi A; De Totero D; Lemoli RM; Fortuna A; Conte R; Crumpton MJ; Stirpe F
Br J Haematol; 1994 Jan; 86(1):97-105. PubMed ID: 7912101
[TBL] [Abstract][Full Text] [Related]
12. Delivery of saporin to human B-cell lymphoma using bispecific antibody: targeting via CD22 but not CD19, CD37, or immunoglobulin results in efficient killing.
Bonardi MA; French RR; Amlot P; Gromo G; Modena D; Glennie MJ
Cancer Res; 1993 Jul; 53(13):3015-21. PubMed ID: 7686448
[TBL] [Abstract][Full Text] [Related]
13. Response of refractory Hodgkin's disease to monoclonal anti-CD30 immunotoxin.
Falini B; Bolognesi A; Flenghi L; Tazzari PL; Broe MK; Stein H; Dürkop H; Aversa F; Corneli P; Pizzolo G
Lancet; 1992 May; 339(8803):1195-6. PubMed ID: 1349939
[TBL] [Abstract][Full Text] [Related]
14. Characteristics and performance of a bispecific F (ab'gamma)2 antibody for delivering saporin to a CD7+ human acute T-cell leukaemia cell line.
Flavell DJ; Cooper S; Morland B; Flavell SU
Br J Cancer; 1991 Aug; 64(2):274-80. PubMed ID: 1716453
[TBL] [Abstract][Full Text] [Related]
15. Response of B-cell lymphoma to a combination of bispecific antibodies and saporin.
French RR; Bell AJ; Hamblin TJ; Tutt AL; Glennie MJ
Leuk Res; 1996 Jul; 20(7):607-17. PubMed ID: 8795695
[TBL] [Abstract][Full Text] [Related]
16. Antitumor activity of anti-CD30 immunotoxin (Ber-H2/saporin) in vitro and in severe combined immunodeficiency disease mice xenografted with human CD30+ anaplastic large-cell lymphoma.
Pasqualucci L; Wasik M; Teicher BA; Flenghi L; Bolognesi A; Stirpe F; Polito L; Falini B; Kadin ME
Blood; 1995 Apr; 85(8):2139-46. PubMed ID: 7718885
[TBL] [Abstract][Full Text] [Related]
17. Induction of apoptosis by ribosome-inactivating proteins and related immunotoxins.
Bolognesi A; Tazzari PL; Olivieri F; Polito L; Falini B; Stirpe F
Int J Cancer; 1996 Nov; 68(3):349-55. PubMed ID: 8903477
[TBL] [Abstract][Full Text] [Related]
18. Bispecific monoclonal antibodies for the targeting of type I ribosome-inactivating proteins against hematological malignancies.
Ferrini S; Sforzini S; Canevari S
Methods Mol Biol; 2001; 166():177-92. PubMed ID: 11217367
[No Abstract] [Full Text] [Related]
19. Therapy of human T-cell acute lymphoblastic leukaemia with a combination of anti-CD7 and anti-CD38-SAPORIN immunotoxins is significantly better than therapy with each individual immunotoxin.
Flavell DJ; Boehm DA; Noss A; Warnes SL; Flavell SU
Br J Cancer; 2001 Feb; 84(4):571-8. PubMed ID: 11207056
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of immunotoxins containing single-chain ribosome-inactivating proteins and an anti-CD22 monoclonal antibody (OM124): in vitro and in vivo studies.
Bolognesi A; Tazzari PL; Olivieri F; Polito L; Lemoli R; Terenzi A; Pasqualucci L; Falini B; Stirpe F
Br J Haematol; 1998 Apr; 101(1):179-88. PubMed ID: 9576199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
